The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus.
 
Robin Kate Kelley
Consulting or Advisory Role - Lilly
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune; Merck Sharp & Dohme; Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Tekmira (Inst)
 
Mariam Rodriguez Lee
No Relationships to Disclose
 
Jimmy Hwang
No Relationships to Disclose
 
John Dozier Gordan
No Relationships to Disclose
 
Halla Sayed Nimeiri
No Relationships to Disclose
 
Andrea Grace Bocobo
No Relationships to Disclose
 
Sheetal Mehta Kircher
No Relationships to Disclose
 
Advaita Kanakamedala
No Relationships to Disclose
 
Mary Frances Mulcahy
No Relationships to Disclose
 
Al Bowen Benson
Consulting or Advisory Role - Alchemia; Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; Genomic Health; Infinity Pharmaceuticals; IntegraGen; Lilly/ImClone; Merck Serono; Merck/Schering Plough; National Cancer Institute; Pharmacyclics; Precision Therapeutics; Sanofi; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Vicus Therapeutics
Research Funding - advanced accelerator applications; Alchemia; Amgen; Astellas Pharma; AVEO; Bayer/Onyx; EMD Serono (Inst); Genentech (I); Gilead Sciences; Infinity Pharmaceuticals; Merck Serono (Inst); Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Dava Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology
 
Peter Kuhn
Leadership - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Research Funding - Epic Sciences
Patents, Royalties, Other Intellectual Property - Epic Sciences
 
Alan P. Venook
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Onyx (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Halozyme; Merck Serono; Roche